Asahi Kasei Medical Europe
VC Fund
Frankfurt, Germany
Asahi Kasei Medical Europe is a developer and manufacturer of medical devices, dialyzers, therapeutic apheresis products, leukocyte reduction filters, and virus removal filters. It was founded in 1981 and is headquartered in Frankfurt.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Asahi Kasei Medical Europe invests in
Stages Asahi Kasei Medical Europe invests in
Countries Asahi Kasei Medical Europe invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Pamela Norton
|
|||
|
Hideki Tsutsumi
|
|||
Investment Focus
Industry
- Manufacturing 2 (67%)
- Health Care 1 (33%)
- Biotechnology 1 (33%)
- Medical Device 1 (33%)
- Pharmaceutical 1 (33%)
Stage
- Series A 1 (33%)
- Series B 1 (33%)
- Private Equity 1 (33%)
Country
- United States 2 (67%)
- Israel 1 (33%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Pamela Norton
Director Of Business Development
|
Director Of Business Development | Total investments: 0 | Find email | |
|
Hideki Tsutsumi
President
|
President | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Fize Medical offers novel tools for reliable, monitoring of patient, its initial solution is a way to track renal output continuously. | Series B / Sep 17, 2026 | ||
| IVexSol is a lentiviral vector production platform that supplies a consistent source of vectors for successful gene therapy programs. The platform's low-cost, highly scalable Intelligent Vector Solutions are intended to alleviate the vector supply bottleneck and increase access to life-saving treatments for patients.Intelligent VectorSolutions from iVexSol are revolutionizing the production of LVVs, which are gene delivery vehicles that are a critical raw material in the manufacture of life-changing cell and gene therapies (CGTs). The technology platform employs banks of vector-producing cells to produce LVV in significantly greater quantities than current approaches while allowing for the rapid scale-out required for global demand, all within a smaller manufacturing footprint. These advancements allow for shorter clinical development timelines, lower costs, and, ultimately, greater global access for patients who are waiting for these transformative medicines. | $23.8M / Series A / Jan 26, 2023 | ||
| Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration. The company was formerly known as Genomic Profiling Systems and changed its name to RapidMicro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts. | $120M / Private Equity / May 20, 2020 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Asahi Kasei Medical Europe invest in?
Asahi Kasei Medical Europe invests primarily in Manufacturing, Health Care and Biotechnology startups, most often at Series A and Series B stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Asahi Kasei Medical Europe?
Public channels for Asahi Kasei Medical Europe include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Asahi Kasei Medical Europe?
The team at Asahi Kasei Medical Europe includes Pamela Norton (Director Of Business Development) and Hideki Tsutsumi (President). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
